Bank Pictet & Cie Europe AG Has $7.25 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Bank Pictet & Cie Europe AG increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 129,024 shares of the medical research company’s stock after acquiring an additional 1,547 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Exact Sciences were worth $7,250,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Asset Planning Inc acquired a new stake in shares of Exact Sciences during the fourth quarter valued at approximately $40,000. Walkner Condon Financial Advisors LLC raised its holdings in shares of Exact Sciences by 6.7% during the fourth quarter. Walkner Condon Financial Advisors LLC now owns 8,517 shares of the medical research company’s stock valued at $447,000 after acquiring an additional 534 shares during the period. Vontobel Holding Ltd. raised its holdings in shares of Exact Sciences by 47.0% during the fourth quarter. Vontobel Holding Ltd. now owns 5,833 shares of the medical research company’s stock valued at $328,000 after acquiring an additional 1,865 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Exact Sciences during the fourth quarter valued at approximately $478,000. Finally, Kestra Private Wealth Services LLC raised its holdings in shares of Exact Sciences by 22.9% during the fourth quarter. Kestra Private Wealth Services LLC now owns 8,387 shares of the medical research company’s stock valued at $471,000 after acquiring an additional 1,564 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $49.31 on Friday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The firm’s fifty day simple moving average is $56.15 and its 200 day simple moving average is $60.09. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $9.13 billion, a PE ratio of -42.14 and a beta of 1.24.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on EXAS shares. Benchmark restated a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Robert W. Baird cut their target price on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group cut their target price on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Piper Sandler cut their target price on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Finally, BTIG Research increased their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.